6CM
ANTH

683 Capital Management’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History

683 Capital Management’s Portfolio ANTH Stock Details ANTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-276,809
Closed -$399K – 174
2017
Q4 		$399K Buy
+276,809
New +$476K 0.03% 122

Other funds holding ANTH

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

683 Capital Management's ANTH Position: Q1 2018 in Review

683 Capital Management sold out of Anthera Pharmaceuticals, Inc. (ANTH) in Q1 2018, closing a stake of 276,809 shares — an estimated $399K sold.

683 Capital Management first reported a position in ANTH in Q4 2017 and held it in 1 quarter. The position peaked at $399K in Q4 2017. 28 funds tracked by Wall St. Rank hold ANTH as of Q1 2018.

  • 683 Capital Management reported no remaining Anthera Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
  • 683 Capital Management sold 276,809 Anthera Pharmaceuticals, Inc. shares in Q1 2018, an estimated $399K.
  • 683 Capital Management first reported a position in Anthera Pharmaceuticals, Inc. in Q4 2017 and held it in 1 quarter.
  • 683 Capital Management's Anthera Pharmaceuticals, Inc. position peaked at $399K in Q4 2017.
  • 28 funds tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q1 2018.

Based on 683 Capital Management's 13F filing for Q1 2018, filed 15 May 2018.